G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis

References

• McDuffie HH, Pahwa P, Karunanayake CP, et al. Clustering of cancer among families of cases with hodgkin lymphoma (HL), multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), soft tissue sarcoma (STS) and control subjects. BMC Cancer. 2009;9(1):1. doi:10.1186/1471-2407-9-70.
   PubMedGoogle Scholar
• Zhang L, Ghielmini M, Cheson BD, et al. Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treat Rev. 2017;58:34–11. doi:10.1016/j.ctrv.2017.05.007.
   PubMed Web of Science ®Google Scholar
• Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240–5247. doi:10.1200/JCO.2007.15.5507.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Bahlis NJ, et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9(6):e403–e414. doi:10.1016/S2352-3026(22)00103-X.
   PubMed Web of Science ®Google Scholar
• Lemieux C, Ahmad I, Bambace NM, et al. Evaluation of the impact of autologous hematopoietic stem cell transplantation on the quality of life of older patients with lymphoma. Biol Blood Marrow Transplant. 2020;26(1):157–161. doi:10.1016/j.bbmt.2019.09.007.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi:10.1182/blood-2018-07-861641.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Meisenberg BR, Reece DE, et al. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and hodgkin lymphoma. Bone Marrow Transplant. 2004;33(8):781–787. doi:10.1038/sj.bmt.1704424.
   PubMed Web of Science ®Google Scholar
• Schuler E, Boughoufala S, Rautenberg C, et al. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Ann Hematol. 2019;98(5):1225–1235. doi:10.1007/s00277-019-03670-6.
   PubMed Web of Science ®Google Scholar
• Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–1348. doi:10.1126/science.1191536.
   PubMed Web of Science ®Google Scholar
• Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther. 2014;14(7):983–993. doi:10.1517/14712598.2014.905537.
   PubMed Web of Science ®Google Scholar
• García-García I, Cid J, Carbassé G, et al. Comparison between standard and high dose of G-CSF for mobilization of hematopoietic progenitors cells in patients and healthy donors. Transfus Med Rev. 2022;36(3):159–163. doi:10.1016/j.tmrv.2022.06.004.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167. doi:10.1200/JCO.2006.08.8823.
   PubMed Web of Science ®Google Scholar
• Rossi G, Skert C, Morello E, et al. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. Hematol Oncol. 2015;33(3):125–132. doi:10.1002/hon.2148.
   PubMed Web of Science ®Google Scholar
• Shah H, Kim S, Singh P, et al. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol. 2020;95(2):198–204. doi:10.1002/ajh.25672.
   PubMed Web of Science ®Google Scholar
• Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011;71(12):1623–1647. doi:10.2165/11206040-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41(4):331–338. doi:10.1038/sj.bmt.1705908.
   PubMed Web of Science ®Google Scholar
• Sureda A, Chabannon C, Masszi T, et al. Analysis of data collected in the european society for blood and marrow transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor. Bone Marrow Transplant. 2020;55(3):613–622. doi:10.1038/s41409-019-0693-z.
   PubMed Web of Science ®Google Scholar
• Steiner N, Göbel G, Mauser L, et al. Poor mobilizers in lymphoma but not myeloma patients had significantly poorer Progression-Free survival after autologous stem cell transplantation: results of a large retrospective, single-Center observational study. Cancers (Basel). 2023;15(3):608. doi:10.3390/cancers15030608.
   PubMed Web of Science ®Google Scholar
• Morris C, Chabannon C, Masszi T, et al. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplant. 2020;55(2):356–366. doi:10.1038/s41409-019-0676-0.
   PubMed Web of Science ®Google Scholar
• Ruan T, Yue Y, Lu W, et al. Association between low ambient temperature during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. Chin Med J (Engl). 2023;136(19):2307–2315. doi:10.1097/CM9.0000000000002361.
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang H, Chen H, et al. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in chinese patients with non-Hodgkin’s lymphoma: a randomized phase 3 study. Transfusion. 2018;58(1):81–87. doi:10.1111/trf.14426.
   PubMed Web of Science ®Google Scholar
• Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2011;51(5):968–975. doi:10.1111/j.1537-2995.2010.02896.x.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34(+) counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition. Transfus Apher Sci. 2012;46(3):257–262. doi:10.1016/j.transci.2012.03.011.
   PubMed Web of Science ®Google Scholar
• Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009;15(2):249–256. doi:10.1016/j.bbmt.2008.11.028.
   PubMed Web of Science ®Google Scholar
• Stewart DA, Smith C, MacFarland R, et al. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009;15(1):39–46. doi:10.1016/j.bbmt.2008.10.018.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortega I, Querol S, Encuentra M, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34 + cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant. 2015;50(1):34–39. doi:10.1038/bmt.2014.196.
   PubMed Web of Science ®Google Scholar
• Ri M, Matsue K, Sunami K, et al. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in japanese patients with multiple myeloma. Int J Hematol. 2017;106(4):562–572. doi:10.1007/s12185-017-2255-8.
   PubMed Web of Science ®Google Scholar
• Ray GK, Jena RK, Panda T, et al. Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation. Hematol Transfus Cell Ther. 2021;43(4):402–409. doi:10.1016/j.htct.2020.04.011.
   PubMedGoogle Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–1056. doi:10.1016/j.bbmt.2008.07.004.
   PubMed Web of Science ®Google Scholar
• Nahi H, Celanovic M, Liu Q, et al. A pilot, exploratory, randomized, phase II safety study evaluating tumor cell mobilization and apheresis product contamination in patients treated with granulocyte colony-stimulating factor alone or plus plerixafor. Biol Blood Marrow Transplant. 2019;25(1):34–40. doi:10.1016/j.bbmt.2018.08.020.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, Stadtmauer EA, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin’s lymphoma or multiple myeloma. Am J Hematol. 2013;88(12):1017–1023. doi:10.1002/ajh.23561.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Nademanee AP, Micallef IN, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-hodgkin lymphoma and low circulating peripheral blood CD34(+). Biol Blood Marrow Transplant. 2013;19(4):670–675. doi:10.1016/j.bbmt.2013.01.005.
   PubMed Web of Science ®Google Scholar
• Matsue K, Kumagai K, Sugiura I, et al. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 2018;108(5):524–534. doi:10.1007/s12185-018-2505-4.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Chute JP, Gasparetto C, et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant. 2012;47(8):1051–1055. doi:10.1038/bmt.2011.217.
   PubMed Web of Science ®Google Scholar
• Haverkos BM, Huang Y, Elder P, et al. A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2017;52(4):561–566. doi:10.1038/bmt.2016.304.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–5726. doi:10.1182/blood-2008-08-174946.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized Double-Blind Placebo-Controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767–4773. doi:10.1200/JCO.2008.20.7209.
   PubMed Web of Science ®Google Scholar
• Cooper DL, Pratt K, Baker J, et al. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk. 2011;11(3):267–272. doi:10.1016/j.clml.2011.03.014.
   PubMed Web of Science ®Google Scholar
• Andreola G, Babic A, Rabascio C, et al. Plerixafor and filgrastim XM02 (tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. Eur J Haematol. 2012;88(2):154–158. doi:10.1111/j.1600-0609.2011.01719.x.
   PubMed Web of Science ®Google Scholar
• Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1253–1261. doi:10.1016/j.bbmt.2008.08.011.
   PubMed Web of Science ®Google Scholar
• Hübel K, Ostermann H, Glaß B, et al. Plerixafor in non-Hodgkin’s lymphoma patients: a german analysis of time, effort and costs. Bone Marrow Transplant. 2019;54(1):123–129. doi:10.1038/s41409-018-0228-z.
   PubMed Web of Science ®Google Scholar
• Kvistad SAS, Burman J, Lehmann AK, et al. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. J Neurol Neurosurg Psychiatry. 2022;93(8):844–848. doi:10.1136/jnnp-2022-328797.
   PubMed Web of Science ®Google Scholar
• Nie M, Bi XW, Zhang WW, et al. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. Sci Rep. 2016;6(1):23996. doi:10.1038/srep23996.
   PubMedGoogle Scholar
• Steinhardt MJ, Krummenast FC, Rosenwald A, et al. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. J Cancer Res Clin Oncol. 2022;148(1):205–214. doi:10.1007/s00432-021-03663-x.
   PubMed Web of Science ®Google Scholar
• Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplant. 2009;43(10):793–800. doi:10.1038/bmt.2008.384.
   PubMed Web of Science ®Google Scholar
• Musto P, Simeon V, Grossi A, et al. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a gruppo italiano malattie EMatologiche dell’Adulto multiple myeloma working party study. Stem Cell Res Ther. 2015;6(1):64. doi:10.1186/s13287-015-0033-1.
   PubMedGoogle Scholar
• Schmitt M, Publicover A, Orchard KH, et al. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Theranostics. 2014;4(3):280–289. doi:10.7150/thno.7752.
   PubMed Web of Science ®Google Scholar
• Karponi G, Psatha N, Lederer CW, et al. Plerixafor + G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015;126(5):616–619. doi:10.1182/blood-2015-03-629618.
   PubMed Web of Science ®Google Scholar
• Karres D, Ali S, van Hennik PB, et al. EMA recommendation for the pediatric indications of plerixafor (mozobil) to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in children with lymphoma or malignant solid tumors. Oncologist. 2020;25(6):e976–e981. doi:10.1634/theoncologist.2019-0898.
   PubMed Web of Science ®Google Scholar
• Afifi S, Adel NG, Devlin S, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant. 2016;51(4):546–552. doi:10.1038/bmt.2015.322.
   PubMed Web of Science ®Google Scholar
• Veltri L, Cumpston A, Shillingburg A, et al. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015;17(12):1785–1792. doi:10.1016/j.jcyt.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Mohty M, Duarte RF, Croockewit S, et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011;25(1):1–6. doi:10.1038/leu.2010.224.
   PubMed Web of Science ®Google Scholar
• Li Z, Hardij J, Evers SS, et al. G-CSF partially mediates effects of sleeve gastrectomy on the bone marrow niche. J Clin Invest. 2019;129(6):2404–2416. doi:10.1172/JCI126173.
   PubMed Web of Science ®Google Scholar
• Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010(1):474–480. doi:10.1182/asheducation-2010.1.474.
   PubMedGoogle Scholar